---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-004616"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2024-01-16T23:59:59+00:00"
generated_at: "2026-06-06T23:17:45.478871+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA approves CRISPR's CASGEVY for transfusion-dependent beta thalassemia in patients 12+

## Summary
- U.S. FDA approved CASGEVY (exagamglogene autotemcel) on Jan 16, 2024 for transfusion-dependent beta thalassemia in patients 12 years and older.
- CASGEVY is a CRISPR/Cas9 gene-edited cell therapy developed by CRISPR Therapeutics.
- The approval expands treatment options for patients with transfusion-dependent beta thalassemia.

## SEC filing metadata
- accession: 0000950170-24-004616
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2024-01-16T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017024004616/0000950170-24-004616-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017024004616/crsp-20240116.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-004616
- JSON: https://secwatch.observer/filing/0000950170-24-004616.json
- Plain text: https://secwatch.observer/filing/0000950170-24-004616.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.